SHANGHAI, May 8, 2024
/PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical
biopharmaceutical company focused on autoimmune diseases and
oncology, will feature Dr. Lin Shen
from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting in
Chicago. Dr. Shen will present the
results from the Phase I/II clinical study of MHB088C, a
well-differentiated B7-H3-targeting antibody-drug conjugate (ADC)
for recurrent or metastatic solid tumors, in an oral
presentation.
Oral Presentation
Abstract Title: Results of a
Phase 1/2 Study of MHB088C: a Novel B7-H3 Antibody-Drug Conjugate
(ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in
Recurrent or Metastatic Solid Tumors
Session Title: Developmental Therapeutics – Molecularly
Targeted Agents and Tumor Biology
Session Date and Time: 6/3/2024; 8:00
AM-9:30 AM CDT
Presentation Time/Duration: 8:00 AM – 8:06 AM CDT
Presenter: Dr. Lin Shen
Abstract ID: 3012
About MHB088C
MHB088C is a novel B7-H3 ADC generated through Minghui's
SuperTopoiTM ADC platform. Minghui's proprietary payload is 5 to 10 times more
potent than Dxd, retaining key advantages such as bystander
effect while eliminating the risk of interstitial lung disease.
Conjugated with Minghui's proprietary B7-H3 antibody, which has
superior binding and internalization compared to the competitor's
antibodies, MHB088C has demonstrated remarkable anti-tumor efficacy
across various cancer types. It was 3 to
10 times more potent in killing tumor cells than the competitor's
compound in xenograft models.
Preclinical GLP tox studies revealed an excellent safety
profile, with no unique toxicities, particularly no pulmonary
toxicities. The highest non-severely toxic dose (HNSTD) was
identified at 30 mg/kg, administered once every two weeks (Q2W) for
a total of seven doses. The first patient in the Phase I/II study
was enrolled on June 20, 2023. Since
then, over 150 patients with different tumor types have been
enrolled and received at least one dose of MHB088C, showing
promising efficacy and a favorable safety profile. Registrational
trials for selected tumor types are expected to start by the end of
the year.
About Minghui Pharmaceutical
Minghui Pharmaceutical, Inc. is a late-stage clinical
biopharmaceutical company dedicated to developing innovative
medicines for unmet medical needs in oncology and autoimmune
diseases. Leveraging the expertise in medical science and the
proprietary technology platforms, the company is developing a rich
clinical-stage pipeline including a variety of first-in-class or
best-in-class product candidates. For more information, please
visit www.minghuipharma.com.
Forward-Looking Statements
This press release provided by Minghui Pharmaceutical Inc. (the
"Company") contains forward-looking statements within the meaning
of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995, which may be accompanied by such
words as "aim," "anticipate," "believe," "could," "estimate,"
"expect," "forecast," "intend," "may," "plan," "potential,"
"possible," "predict," "should," "will," "would" or words of
similar meaning. These statements are based on the Company's
current beliefs and expectations and subject to risks and
uncertainties that may cause actual results to differ materially
from those set forth in the statements herein. Risks and
uncertainties include but not limited to: general industry
conditions and competition; changes in economic and financial
conditions of the Company's and the collaborators' businesses; the
risk that clinical trials are discontinued or delayed for any
reasons, including for efficacy, safety, enrollment, or
manufacturing; the risk that success in early stage clinical trials
may not be predictive of results in later stage trials or trials of
other potential indications; the risk that positive results in a
clinical trial may not be replicated in subsequent or confirmatory
trials; expectations for regulatory approvals; challenges to
obtain, maintain and enforce patents and other intellectual
property protection for the Company's product(s) and product
candidate(s). These forward-looking statements speak only as of the
date they are posted to this website, and the Company undertakes no
obligation to update any forward-looking statements contained
herein.
View original
content:https://www.prnewswire.com/news-releases/minghui-pharmaceutical-to-present-the-phase-iii-study-of-mhb088c-b7-h3-adc-for-the-treatment-of-patients-with-recurrent-or-metastatic-solid-tumors-in-late-breaking-oral-presentation-at-the-2024-asco-annual-meeting-302139458.html
SOURCE Minghui Pharmaceutical, Inc.